Xeroderma pigmentosum, which is known as XP, is a rare inherited disease characterized the maximum sensitivity of the sun and ultraviolet rays, resulting in pigment changes, sunburn and increased rates of mucus membrane cancers. It is an autosomal recessive disorder with the possibility of starting a 10,000-fold growth in skin cancer in patients having XP below the age of 20 years. It was in the late 19th century when dermatologist Moritz Kaposi led the road to understanding XP. During 1874, Kaposi used the term “xeroderma” to describe four patients with this disease. Dr. Albert Neisser reported the first XP case with neurological indications and later in the second decade, DeSanctis and Cacchione outlined XP with acute neurological deficiency known as “DeSanctis-Cacchione syndrome” [1].

References

1. DiGiovanna J and Kraemer K. “Shining a Light on Xeroderma Pigmentosum”. Journal of Investigative Dermatology3 (2012): 785-796.
2. Mareddy S., et al. “Xeroderma Pigmentosum: Man Deprived of His Right to Light”. The Scientific World Journal (2013): 1-8.
3. Conditions G. “Xeroderma pigmentosum: MedlinePlus Genetics” (2020).
4. Black J. “Xeroderma Pigmentosum”. Head and Neck Pathology 2 (2016): 139-144.

Citation

Citation: Dhvani H Kuntawala. “Xeroderma Pigmentosum". Acta Scientific Biotechnology 2.1 (2021): .

Copyright

Copyright: © 2021 Dhvani H Kuntawala. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.